ArticleBreast cancer research and treatment2026

Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+/HER2- early breast cancer and eligibility for adjuvant CDK4/6 inhibitors.

Santiago Terán et al.PubMed ↗Publisher ↗

No numbers read from the abstract.